SCHEMBL107604

SCHEMBL107604

Cn1cc(Cl)cc(Nc2ccc(=O)n(Cc3ccccc3)n2)c1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 5/20 0.50
▸ PTGS2 P35354 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ BRD4 O60885 2/20 0.39
▸ MAPK14 Q16539 1/20 0.38
▸ PTGDR2 Q9Y5Y4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL104441 0.71 MAPK14 (0.34) METMAPTPDE4BMAPK14
SCHEMBL15815964 0.69 PDE4A (0.63) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL15815661 0.69 MET (0.57) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL15836998 0.69 MET (0.53) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL15815194 0.68 MET (0.52) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL104990 0.67 ALDH1A1 (0.58) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL15815769 0.67 PDE4B (0.54) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL14074040 0.66 PTGS2 (0.62) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL6376456 0.64 ALDH1A1 (0.55) METPTGS2KDM4EALDH1A1MAPT
SCHEMBL23762937 0.63 RAB9A (0.43) KDM4EALDH1A1L3MBTL1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205564-B1 NOVEL KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2014-07-30 — — EP disclosed
EP-2426109-B1 NOVEL KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2013-12-18 — — EP disclosed
EP-2426109-A1 NOVEL KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-03-07 — — EP disclosed
US-7943618-B2 Btk protein kinase inhibitors ROCHE PALO ALTO LLC (US) 2011-05-17 — — US disclosed
CN-101835755-A Novel kinase inhibitors HOFFMANN LA ROCHE 2010-09-15 — — CN disclosed
US-20090105209-A1 BTK protein kinase inhibitors ROCHE PALO ALTO LLC 2009-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105209-A1 BTK protein kinase inhibitors BTK, SYK, LYN MET 4735/4885PTGS2 2613/4885KDM4E 1225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback